Organ-restricted vascular delivery of nanoparticles for lung cancer therapy

Nanomedicines hold immense promise for a number of devastating diseases due to the ability to custom-design both the carrier and cargo. However, their clinical implementation has been hampered by physicochemical and biological barriers and off-target deposition which impair cell specific targeting,...

Full description

Saved in:
Bibliographic Details
Published inbioRxiv
Main Authors Deniz Ali Bolukbas, Datz, Stefan, Meyer-Schwickerath, Charlotte, Morrone, Carmela, Doryab, Ali, Goessl, Dorothee, Vreka, Malamati, Yang, Lin, Argyo, Christian, Van Rijt, Sabine Helena, Lindner, Michael, Eickelberg, Oliver, Stoeger, Tobias, Schmid, Otmar, Lindstedt, Sandra, Stathopoulos, Georgios T, Bein, Thomas, Wagner, Darcy E, Meiners, Silke
Format Paper
LanguageEnglish
Published Cold Spring Harbor Cold Spring Harbor Laboratory Press 06.03.2020
Subjects
Cancer therapies
Lung cancer
Nanoparticles
Trachea
Tumor cells
Tumors
Online AccessGet full text

Cover

More Information
Summary:Nanomedicines hold immense promise for a number of devastating diseases due to the ability to custom-design both the carrier and cargo. However, their clinical implementation has been hampered by physicochemical and biological barriers and off-target deposition which impair cell specific targeting, especially in internal organs. This study reports a new delivery approach using organ-restricted vascular delivery to allow for direct administration and recirculation of stimuli-responsive nanoparticles to promote cellular uptake into an organ of interest. Using this technique, nanoparticles reach the interior of dense tumors and are selectively taken up by lung cancer cells. Importantly, this surgical approach is essential as the same nanoparticles do not reach lung tumor cells upon systemic or intratracheal administration. Organ-restricted vascular delivery thus opens up new avenues for optimized nanotherapies for cancer and other diseases.
DOI:10.1101/2020.03.05.969212